Resistance to Proteasome Inhibitors in Cancer (eBook)

Q. Ping Dou, Ph.D. is Professor of Pathology, Cancer Biology and Pharmacology at Wayne State University School of Medicine. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. He also serves on multiple editorial boards, including The Open Leukemia Journal, Journal of Clinical Oncology, Frontiers of Bioscience, to name a few.

Preface - Q Ping Dou Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer - Sara M. Schmitt, Rahul R. Deshmukh, Q. Ping DouResistance to proteasome inhibitors in multiple myeloma - Francesca Cottini MD, Anna Guidetti MD, Claudia Paba Prada MD, Teru Hideshima MD PhD, Michelle Maglio, Cindy Varga MD, Dharminder Chauhan JD PhD, Jacob Laubach MD, Kenneth C Anderson MD, Paul G Richardson MDOvercoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma - Hans C. Lee, M.D., and Robert Z. Orlowski, Ph.D., M.D.Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis - Jeffrey A. Zonder, MDProfiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy - Amit Mitra, Holly Stessman, John Shaughnessy, and Brian Van NessTargeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition - Michael Batalo, Prithviraj Bose, Beata Holkova, Steven GrantPre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies - Jacqueline Cloos, Denise Niewerth, Gerrit JansenOvercoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches - Jason I. Kass, Jennifer R. Grandis and Daniel E. JohnsonTargeting the proteasome pathway for the treatment of solid tumors - Nisar Ahmad, Elias Anaissie  and James J. Driscoll